Northwestern Medicine formerly Northwestern Memorial Healthcare, is a non-profit healthcare system affiliated with the Northwestern University Feinberg School of Medicine, in Chicago, Illinois. Members include research hospitals, acute care facilities, and academic centers. Northwestern Medicine's flagship hospital is the nationally-ranked, Northwestern Memorial Hospital which is also the regions tertiary hospital for adults. Along with their 10 hospitals and physicians offices, Northwestern Medicine operates a network of urgent care centers across the region. While not directly operated with Northwestern Medicine, the network maintains close affiliations with the nearby Ann & Robert H. Lurie Children's Hospital of Chicago and the Shirley Ryan AbilityLab, collaborating with them for many of their services.
AIM The "2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia" retires and replaces the "2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol." METHODS A comprehensive literature search was conducted from October 2024 to December 2024 to identify clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. STRUCTURE The focus of this clinical practice guideline is to address the evaluation, management, and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a).
For small primary umbilical hernias, suture-only repair remains common, yet there is limited comparative evidence guiding suture material selection. Our study compared the recurrence and complication rates of primary umbilical hernias using permanent or absorbable sutures. We performed a retrospective cohort study using the Abdominal Core Health Quality Collaborative (ACHQC), a national, prospectively maintained hernia registry. Adults undergoing elective, open primary umbilical hernia repair without mesh between May 2014 and February 2024 with ≥ 1-year follow-up were included (N = 1,140). Patients were stratified by suture type: slowly absorbable (n = 500) versus permanent (n = 640). The primary endpoint was 1-year hernia recurrence; secondary endpoints included 30-day surgical site infection (SSI), surgical site occurrence (SSO), readmission, reoperation, and patient-reported outcomes (HerQLes and PROMIS). Multivariable logistic and linear regression models adjusted for suture configuration, BMI, COPD, ascites, smoking, and diabetes. One-year recurrence rates were similar between slowly absorbable and permanent suture repairs (6
PURPOSE:Health-system pharmacists play a crucial role in monitoring the pharmaceutical pipeline to manage formularies, allocate resources, and optimize clinical programs for new therapies. This article aims to support pharmacists by providing updates on new and anticipated novel drug approvals. SUMMARY:Selected drug approvals anticipated in the 12-month period covering the fourth quarter of 2025 through the third quarter of 2026 are reviewed. The analysis emphasizes drugs expected to have significant clinical and financial impact in hospitals and clinics, as selected from 41 novel drugs awaiting US Food and Drug Administration approval. This year's pipeline features novel therapies for various disease states, including rare diseases, Wiskott-Aldrich syndrome, and mucopolysaccharidosis type II, as well as targeted cancer treatments and cell and gene therapies. CONCLUSION:Novel therapies continue to strengthen the current drug pipeline.
PURPOSE:Health-system pharmacists play a crucial role in monitoring the pharmaceutical pipeline to manage formularies, allocate resources, and optimize clinical programs for new therapies. This article aims to support pharmacists by providing updates on new and anticipated novel drug approvals. SUMMARY:Selected drug approvals anticipated in the 12-month period covering the 4 quarters of 2026 are reviewed. The analysis emphasizes drugs expected to have significant clinical and financial impact in hospitals and clinics, as selected from 52 novel drugs awaiting US Food and Drug Administration approval. This year's pipeline features novel therapies for various disease states, including rare and inherited genetic disorders as well as immunologic and inflammatory diseases, and continued advancements in both targeted oncology and gene therapies. CONCLUSION:Novel therapies continue to strengthen the current drug pipeline.
The growing number of bariatric and oncologic gastrointestinal and hepatopancreatobiliary surgeries has fueled the increased need for biliary interventions in patients with surgically altered anatomy (SAA), where standard endoscopic retrograde cholangiopancreatography (ERCP) is often unfeasible. Traditional alternative methods, such as enteroscopy- or laparoscopy-assisted ERCP, are associated with technical and logistical limitations. Endoscopic ultrasound (EUS)-directed ERCP uses lumen-apposing metal stents (LAMS) to create temporary anastomoses between adjacent lumens, thus restoring access for standard ERCP. These procedures include EUS-directed transgastric (EDGE), transenteric (EDEE), transduodenal (EDDE), and transcholedochal/transcystic (EDCE) ERCP. This review provides an evidence-based analysis of the available techniques and comparative outcomes, with a particular focus on technical and strategic aspects including: (1) how to create an EUS-guided anastomosis across different surgical scenarios; (2) how to perform a through-the-LAMS ERCP, including endoscope and accessory selection, ERCP timing and LAMS fixation; and (3) how to manage the fistula after completion of therapy, including timing of LAMS removal and fistula closure. An algorithm is proposed to guide the endoscopist through the complex decision-making inherent to pancreatobiliary interventions in SAA.
